Jazz Pharmaceuticals PLC
NASDAQ:JAZZ

Watchlist Manager
Jazz Pharmaceuticals PLC Logo
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Watchlist
Price: 162.16 USD -0.06%
Market Cap: 9.9B USD

Jazz Pharmaceuticals PLC
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Jazz Pharmaceuticals PLC
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Interest Income Expense
-$209.1m
CAGR 3-Years
14%
CAGR 5-Years
-18%
CAGR 10-Years
-13%
Perrigo Company PLC
NYSE:PRGO
Interest Income Expense
-$162.9m
CAGR 3-Years
-3%
CAGR 5-Years
-6%
CAGR 10-Years
1%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Interest Income Expense
-$9.7m
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
-7%
G
GH Research PLC
NASDAQ:GHRS
Interest Income Expense
$5.7m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cosmo Pharmaceuticals NV
SIX:COPN
Interest Income Expense
€3.5m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
-10%
Ovoca Bio PLC
LSE:OVB
Interest Income Expense
€246k
CAGR 3-Years
-26%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
No Stocks Found

Jazz Pharmaceuticals PLC
Glance View

In the bustling world of global pharmaceuticals, Jazz Pharmaceuticals PLC has carved out a niche for itself through its focus on specialty pharmaceuticals addressing unmet medical needs. Founded in 2003, Jazz has grown significantly by acquiring and developing unique products that serve smaller patient populations but address significant health challenges. Its journey is one of careful strategy and thoughtful innovation. The company first gained attention with its sleep disorder portfolio, most notably Xyrem, a treatment for narcolepsy that quickly became a cornerstone of its revenue stream. Jazz's adeptness at navigating complex regulatory and market environments has played a crucial role in its success, allowing it to maintain a stronghold in niche therapeutic markets. Building on its initial successes, Jazz began to diversify its portfolio, expanding into oncology and neuroscience. The acquisition of companies like Celator Pharmaceuticals and GW Pharmaceuticals was a strategic move to broaden its research capabilities and tap into the lucrative, yet challenging, segments of cancer and cannabinoid therapies. Jazz’s pipeline is rich with promising candidates, reflecting its commitment to long-term growth through innovation. Central to its business model is the commercialization of these specialized, high-value drugs, which are marketed to healthcare providers and directly impact patient outcomes. By focusing on diseases with few effective treatments, Jazz positions itself as a leader in transforming lives, all while sustaining its financial health through carefully managed margins and a global reach in its distribution and research efforts.

JAZZ Intrinsic Value
303.89 USD
Undervaluation 47%
Intrinsic Value
Price

See Also

What is Jazz Pharmaceuticals PLC's Interest Income Expense?
Interest Income Expense
-209.1m USD

Based on the financial report for Sep 30, 2025, Jazz Pharmaceuticals PLC's Interest Income Expense amounts to -209.1m USD.

What is Jazz Pharmaceuticals PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-13%

Over the last year, the Interest Income Expense growth was 16%. The average annual Interest Income Expense growth rates for Jazz Pharmaceuticals PLC have been 14% over the past three years , -18% over the past five years , and -13% over the past ten years .

Back to Top